Publication|Articles|December 2, 2025
Supplements and Featured Publications
- The Transformative Approach of TEVIMBRA® (tislelizumab-jsgr) in Managing ESCC and GC/GEJC
The Transformative Approach of TEVIMBRA® (tislelizumab-jsgr) in Managing ESCC and GC/GEJC
Advertisement
This Clinical Brief was sponsored by BeOne Medicines.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
TrumpRx Launch Brings Savings—and Uncertainty
2
How Do GLP-1 Agonists Fit Into Stroke Care?
3
Addressing Disparities at Every Step of the Stroke Care Pathway: Luke Messac, MD, PhD
4
5 Things to Know About the Oral GLP-1 Era
5
